Recruiting Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917 Conditions Breast Diseases, Breast Neoplasms, HER2-low Hormone Receptor Positive Breast Cancer, +13 more Locations University of Arizona — Tucson, Arizona, United States START Los Angeles — Los Angeles, California, United States Skin Cancer Institute — Englewood, Colorado, United States Wayne State University - Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States View all 17 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients NCT06832202 Conditions HER2-low Hormone Receptor Positive Breast Cancer Locations Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China View Trial Details
